Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2015-02-09

FDA Approved: CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE — Supplemental Application (ANI Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental NDA for the combination antihypertensive candesartan cilexetil and hydrochlorothiazide from ANI Pharmaceuticals, expanding its r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Candesartan Cilexetil and Hydrochlorothiazide (Candesartan cilexetil and hydrochlorothiazide)

Snippet

SUPPL AP for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE (CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE)